A small randomized, double-blind, placebo-controlled study (E Scaioli et al. Clin Gastroenterol Hepatol 2018; 16: 1268-75) examined the use of Eicosapentaenoic acid-Free Fatty Acid Form (EPA-FFA) a component of n-3 fish oil for patients with ulcerative colitis UC).
From 2014-2016, the investigators enrolled 60 patients who had partial Mayo score <2 and fecal calprotectin >150 mcg/g who had been receiving stable therapy for at least 3 months. Then they were randomized 1:1 to receive EPA 1000 mg BID or placebo for 6 months.
- 19 of 30 (63%) EPA-FFA group compared with 4 of 30 (13.3%) of placebo-treated group had achieved the primary endpoint of a 100-point reduction in fecal calprotectin at 6 months. OR 12.0, P<.001
- The secondary endpoint of clinical remission was noted in 23 of 30 (77%) in the EPA-FFA group compared with 15 of 30 (50%), OR 3.29, P=.035)
- No serious adverse effects were reported.
- Small number of patients from a single center
- Short follow-up
- In those without clinical relapse, a followup colonoscopy was not performed
My take: In this study EPA-FFA was associated with lower calprotectin and higher rates of remaining in remission. More data are needed.
Related blog posts:
- Spice it up? Curcurmin for ulcerative colitis
- Herbal Medicines for IBD and IBS | gutsandgrowth
- The Search for a Dietary Culprit in IBD | gutsandgrowth
Disclaimer: These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.